Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
AIDS (London, England)|June 17, 2005
SEN virus has an adverse effect on the survival of HIV-positive patientsAbdurrahman Sagir, Ortwin Adams, Mehmet Antakyali, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 17, 2006
Treatment of chronic hepatitis delta with pegylated interferon-alpha2bAndreas Erhardt, Wolfram Gerlich, Christine Starke, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2004
Psychomotor slowing in hepatitis C and HIV infectionHans-Jürgen von Giesen, Tobias Heintges, Naghme Abbasi-Boroudjeni, et al.
Gastroenterology|August 9, 2005
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis CMichael von Wagner, Miriam Huber, Thomas Berg, et al.
Gastroenterology|April 19, 2006
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirinThomas Berg, Michael von Wagner, Samer Nasser, et al.
European Radiology|August 17, 2022
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306Felix O Hofmann, Volker Heinemann, Melvin D'Anastasi, et al.
Oncotarget|December 30, 2017
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2015
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal CancerDominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
British Journal of Cancer|November 6, 2020
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trialVolker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2025
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trialKathrin Heinrich, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Pageof 4